Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma
Saqib Ahmed, Erik Petersen, Ravi Patel, et al.
Expert Review of Clinical Pharmacology (2019) Vol. 12, Iss. 10, pp. 947-951
Closed Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Role of tumor microenvironment in cancer progression and therapeutic strategy
Qingjing Wang, Xueting Shao, Yuxuan Zhang, et al.
Cancer Medicine (2023) Vol. 12, Iss. 10, pp. 11149-11165
Open Access | Times Cited: 171
<p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy</p>
Leilei Ai, Jian Chen, Hao Yan, et al.
Drug Design Development and Therapy (2020) Vol. Volume 14, pp. 3625-3649
Open Access | Times Cited: 139
Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
Pratibha Pandey, Fahad Khan, Huda A. Qari, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 3, pp. 335-335
Open Access | Times Cited: 76
Current status of skin cancers with a focus on immunology and immunotherapy
Mahsa Khayyati Kohnehshahri, Aila Sarkesh, Leila Mohamed Khosroshahi, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 35
Cancer neoantigens as potential targets for immunotherapy
Weijie Ma, Brian Pham, Tianhong Li
Clinical & Experimental Metastasis (2021) Vol. 39, Iss. 1, pp. 51-60
Open Access | Times Cited: 44
PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy
Dan Lü, Zepeng Xu, Ding Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 36
Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening
Katarzyna Ratajczak, Hubert Grel, Piotr Olejnik, et al.
Biosensors and Bioelectronics (2023) Vol. 240, pp. 115644-115644
Open Access | Times Cited: 17
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma
Philip R. Clingan, Rahul Ladwa, Daniel Brungs, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 10, pp. e007637-e007637
Open Access | Times Cited: 17
Update of advanced cutaneous squamous cell carcinoma
Estella de Jong, M.U.P.A. Lammerts, Roel E. Genders, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 36, Iss. S1, pp. 6-10
Open Access | Times Cited: 36
Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy
John Fetse, Zhen Zhao, Hao Liu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 18, pp. 12002-12013
Open Access | Times Cited: 26
Revisiting metallodrugs for the treatment of skin cancers
Carlos Marrote Manzano, Douglas Hideki Nakahata, Raphael Enoque Ferraz de Paiva
Coordination Chemistry Reviews (2022) Vol. 462, pp. 214506-214506
Open Access | Times Cited: 22
Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges
Tuba M. Ansary, Md Razib Hossain, Mayumi Komine, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8530-8530
Open Access | Times Cited: 21
Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology
C. Esnault, David Schrama, Roland Houben, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 778-778
Open Access | Times Cited: 19
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
Omid Kooshkaki, Afshin Derakhshani, Hossein Safarpour, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 5034-5034
Open Access | Times Cited: 32
RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer
Pola Olczak, Ken Matsui, Margaret Wong, et al.
Journal of Virology (2022) Vol. 96, Iss. 13
Open Access | Times Cited: 16
Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC)
Ahmed Mousa, Alexander Enk, Jessica C. Hassel, et al.
Cells (2024) Vol. 13, Iss. 19, pp. 1615-1615
Open Access | Times Cited: 3
An Updated Review of Immune Checkpoint Inhibitors in Cutaneous Oncology: Beyond Melanoma
James P. Pham, Ramon Staeger, Anthony M. Joshua, et al.
European Journal of Cancer (2024) Vol. 214, pp. 115121-115121
Open Access | Times Cited: 3
Opportunities for using in silico‐based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors
Cody J. Peer, Daniel A. Goldstein, Jennifer C. Goodell, et al.
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 9, pp. 1769-1777
Open Access | Times Cited: 27
Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals
Dae Young Lee, Eunji Im, Dahye Yoon, et al.
Seminars in Cancer Biology (2020) Vol. 86, pp. 1033-1057
Closed Access | Times Cited: 25
Development of broadly neutralizing antibodies targeting the cytomegalovirus subdominant antigen gH
Andrea Parsons, Sabrina I. Ophir, J. Andrew Duty, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 15
Dissection of an impact of VDR and RXRA on the genomic activity of 1,25(OH)2D3 in A431 squamous cell carcinoma
Anna Olszewska, Joanna I. Nowak, Kamil Myszczyński, et al.
Molecular and Cellular Endocrinology (2023) Vol. 582, pp. 112124-112124
Open Access | Times Cited: 8
Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1
Adam Mor, Marianne Strazza
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 13
Squamous Cell Carcinoma Arising from Chronic Osteomyelitis in the Extremities: Treatment Approach and Oncological Outcomes—A Systematic Review of the Literature
Mayte Bryce‐Alberti, Marcos R. Gonzalez, Andrés Quevedo-Ramírez, et al.
Journal of Skin Cancer (2022) Vol. 2022, pp. 1-11
Open Access | Times Cited: 13
Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity
Quentin G. Wright, Debottam Sinha, James W. Wells, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e007960-e007960
Open Access | Times Cited: 2
Anti-Tumor Potential of Post-Translational Modifications of PD-1
Xiaoming Xi, Wuli Zhao
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 3, pp. 2119-2132
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top